國立虎尾科技大學 |

Development of Imidazoquinoline Prodrugs for Use in Targeted Immunotherapy of Various Pathologies.

Record Type:	Language materials, manuscript : Monograph/item
Title/Author:	Development of Imidazoquinoline Prodrugs for Use in Targeted Immunotherapy of Various Pathologies./
Author:	Ryan, Austin T.
Description:	1 online resource (243 pages)
Notes:	Source: Dissertations Abstracts International, Volume: 84-05, Section: B.
Contained By:	Dissertations Abstracts International84-05B.
Subject:	Organic chemistry. -
Online resource:	click for full text (PQDT)
ISBN:	9798357547156

Development of Imidazoquinoline Prodrugs for Use in Targeted Immunotherapy of Various Pathologies.
Ryan, Austin T.

Development of Imidazoquinoline Prodrugs for Use in Targeted Immunotherapy of Various Pathologies. - 1 online resource (243 pages)

Source: Dissertations Abstracts International, Volume: 84-05, Section: B.

Thesis (Ph.D.)--Washington State University, 2022.

Includes bibliographical references

The field of immunotherapy has been historically dominated by macromolecular biologic treatments, including monoclonal antibodies, cytokines, and heat-inactivated bacteria. Recent advances in the field have indicated that small molecule immunostimulants can induce anti-cancer and anti-bacterial immunity, and several of these compounds (imiquimod, monophosphoryl lipid A) have acquired FDA approval for the treatment of various types of cancer. However, the clinical success of small molecule immunostimulants in general has been seriously hampered by adverse side-effects associated with indiscriminate immune cell stimulation and systemic inflammation. Our group has recently established a technique termed Bystander Assisted Immunotherapy (BAIT), wherein an enzyme-directed immunostimulant prodrug platform can be selectively metabolized by multi-drug resistant cancer cells to activate immunogenicity. The BAIT mechanism employs an inactive immunostimulant prodrug which is targeted to a pathologically relevant enzyme. Hydrolysis of the prodrug directing group by the enzyme target leads to formation of an active immunostimulant which is then effluxed to the extracellular space where it can engage with nearby immune cells to induce an immune response local to the pathogen. This dissertation expands upon the framework of BAIT by exploring the impact of several parameters including enzyme-directing group, immunostimulant payload, and target cell type. Specifically, we report the development of prodrugs of resiquimod and imiquimod - members of the imidazoquinoline class of toll-like receptor agonists - that are targeted to various hydrolases that are upregulated by cancer cells, β-lactamases that are uniquely expressed in drug-resistant bacteria, and avidin which we have used as a model protein target for our proof-of-concept Ligand-Directed Nitrophenol Carbonate (LDNPC) affinity labeling and drug delivery platform. We envision that these developments will propel our BAIT technology toward in vivo application, with the hope that this drug delivery technique may enhance the safety and efficacy of future small molecule immunotherapies.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2024

Mode of access: World Wide Web

ISBN: 9798357547156Subjects--Topical Terms:

1148722
Organic chemistry.
Subjects--Index Terms:

Bystander-assisted immunotherapyIndex Terms--Genre/Form:

554714
Electronic books.

Development of Imidazoquinoline Prodrugs for Use in Targeted Immunotherapy of Various Pathologies.
LDR:03610ntm a22004097 4500 001 1145455
005 20240624103656.5
006 m o d
007 cr bn ---uuuuu
008 250605s2022 xx obm 000 0 eng d
020 $a 9798357547156
035 $a (MiAaPQ)AAI29261081
035 $a AAI29261081
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Ryan, Austin T. $0 (orcid)0000-0002-3249-1823 $3 1437692
245 1 0 $a Development of Imidazoquinoline Prodrugs for Use in Targeted Immunotherapy of Various Pathologies.
264 0 $c 2022
300 $a 1 online resource (243 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 84-05, Section: B.
500 $a Advisor: Mancini, Rock J.;Berkman, Clifford E.
502 $a Thesis (Ph.D.)--Washington State University, 2022.
504 $a Includes bibliographical references
520 $a The field of immunotherapy has been historically dominated by macromolecular biologic treatments, including monoclonal antibodies, cytokines, and heat-inactivated bacteria. Recent advances in the field have indicated that small molecule immunostimulants can induce anti-cancer and anti-bacterial immunity, and several of these compounds (imiquimod, monophosphoryl lipid A) have acquired FDA approval for the treatment of various types of cancer. However, the clinical success of small molecule immunostimulants in general has been seriously hampered by adverse side-effects associated with indiscriminate immune cell stimulation and systemic inflammation. Our group has recently established a technique termed Bystander Assisted Immunotherapy (BAIT), wherein an enzyme-directed immunostimulant prodrug platform can be selectively metabolized by multi-drug resistant cancer cells to activate immunogenicity. The BAIT mechanism employs an inactive immunostimulant prodrug which is targeted to a pathologically relevant enzyme. Hydrolysis of the prodrug directing group by the enzyme target leads to formation of an active immunostimulant which is then effluxed to the extracellular space where it can engage with nearby immune cells to induce an immune response local to the pathogen. This dissertation expands upon the framework of BAIT by exploring the impact of several parameters including enzyme-directing group, immunostimulant payload, and target cell type. Specifically, we report the development of prodrugs of resiquimod and imiquimod - members of the imidazoquinoline class of toll-like receptor agonists - that are targeted to various hydrolases that are upregulated by cancer cells, β-lactamases that are uniquely expressed in drug-resistant bacteria, and avidin which we have used as a model protein target for our proof-of-concept Ligand-Directed Nitrophenol Carbonate (LDNPC) affinity labeling and drug delivery platform. We envision that these developments will propel our BAIT technology toward in vivo application, with the hope that this drug delivery technique may enhance the safety and efficacy of future small molecule immunotherapies.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2024
538 $a Mode of access: World Wide Web
650 4 $a Organic chemistry. $3 1148722
650 4 $a Immunology. $3 592892
650 4 $a Biochemistry. $3 582831
653 $a Bystander-assisted immunotherapy
653 $a Cancer
653 $a Imidazoquinoline
653 $a Immunotherapy
653 $a Prodrug
653 $a Toll-like receptor
655 7 $a Electronic books. $2 local $3 554714
690 $a 0490
690 $a 0982
690 $a 0487
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a Washington State University. $b Department of Chemistry. $3 1437693
773 0 $t Dissertations Abstracts International $g 84-05B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29261081 $z click for full text (PQDT)